Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature

被引:2
作者
Wu, Min [1 ,2 ]
Liu, Jie [2 ]
Seery, Samuel [3 ]
Meng, Xue [1 ,2 ]
Yue, Jinbo [1 ,2 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Jinan, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[3] Univ Lancaster, Fac Hlth & Med, Hlth Res, Lancaster, England
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; camrelizumab; abscopal effect; pseudoprogression; MLR; C-REACTIVE PROTEIN; IMMUNE-RELATED RESPONSE; CHECKPOINT BLOCKADE; RADIATION-THERAPY; IMPROVED SURVIVAL; SOLID TUMORS; CANCER; PATIENT; MACROPHAGES; RESISTANCE;
D O I
10.3389/fimmu.2021.646085
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There is little evidence around Camrelizumab combined with cytoreductive nephrectomy (CN) and radiotherapy (RT) as a treatment option for metastatic renal cell carcinoma (mRCC). The influence of CN on immune responses and the abscopal effect are not well understood. In this paper, we report a case of anti-programmed cell death-1 (PD-1) treated with combined RT once CN reduced the primary tumor burden (TB). This patient also encountered an increased response to targeted radiotherapy after immune resistance. We also observed a macrophage-to-lymphocyte ratio (MLR) peak, which may be correlated with subsequent pseudoprogression after thoracic radiotherapy. Consequently, even with the disease, this patient has remained stable. This peculiar instance suggests there is a need to investigate the underlying mechanisms of CN in promoting the abscopal effect during immunotherapy when combined with RT. It also suggests that there is a need for further investigation into the role of RT in overcoming immune resistance, and the value of MLR in predicting pseudoprogression. We hypothesize that a heavy tumor burden might suppress the abscopal effect, thereby ensuring that CN promotes it. However, radiotherapy may overcome immune resistance during oligoprogression.
引用
收藏
页数:9
相关论文
共 58 条
  • [1] Better survival in patients with metastasised kidney cancer after nephrectomy: A population-based study in the Netherlands
    Aben, K. K. H.
    Heskamp, S.
    Janssen-Heijnen, M. L.
    Koldewijn, E. L.
    van Herpen, C. M.
    Kiemeney, L. A.
    Oosterwijk, E.
    van Spronsen, D. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (13) : 2023 - 2032
  • [2] Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Puzanov, Igor
    Fishman, Mayer N.
    McDermott, David F.
    Cho, Daniel C.
    Vaishampayan, Ulka
    George, Saby
    Olencki, Thomas E.
    Tarazi, Jamal C.
    Rosbrook, Brad
    Fernandez, Kathrine C.
    Lechuga, Mariajose
    Choueiri, Toni K.
    [J]. LANCET ONCOLOGY, 2018, 19 (03) : 405 - 415
  • [3] Treatment of renal cell carcinoma: Current status and future directions
    Barata, Pedro C.
    Rini, Brian I.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) : 507 - 524
  • [4] PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes
    Ben Nasr, Moufida
    Tezza, Sara
    D'Addio, Francesca
    Mameli, Chiara
    Usuelli, Vera
    Maestroni, Anna
    Corradi, Domenico
    Belletti, Silvana
    Albarello, Luca
    Becchi, Gabriella
    Fadini, Gian Paolo
    Schuetz, Christian
    Markmann, James
    Wasserfall, Clive
    Zon, Leonard
    Zuccotti, Gian Vincenzo
    Fiorina, Paolo
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (416)
  • [5] Novel patterns of response under immunotherapy
    Borcoman, E.
    Kanjanapan, Y.
    Champiat, S.
    Kato, S.
    Servois, V.
    Kurzrock, R.
    Goel, S.
    Bedard, P.
    Le Tourneau, C.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (03) : 385 - 396
  • [6] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
    Cella, David
    Gruenwald, Viktor
    Escudier, Bernard
    Hammers, Hans J.
    George, Saby
    Nathan, Paul
    Grimm, Marc-Oliver
    Rini, Brian, I
    Doan, Justin
    Ivanescu, Cristina
    Paty, Jean
    Mekan, Sabeen
    Motzer, Robert J.
    [J]. LANCET ONCOLOGY, 2019, 20 (02) : 297 - 310
  • [7] Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
    Champiat, Stephane
    Dercle, Laurent
    Ammari, Samy
    Massard, Christophe
    Hollebecque, Antoine
    Postel-Vinay, Sophie
    Chaput, Nathalie
    Eggermont, Alexander
    Marabelle, Aurelien
    Soria, Jean-Charles
    Ferte, Charles
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (08) : 1920 - 1928
  • [8] Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
    Chang, Lee-Shing
    Barroso-Sousa, Romualdo
    Tolaney, Sara M.
    Hodi, F. Stephen
    Kaiser, Ursula B.
    Min, Le
    [J]. ENDOCRINE REVIEWS, 2019, 40 (01) : 17 - 65
  • [9] Chen D., 2020, INT J RADIAT ONCOL, V8, DOI [10.1016/j.ijrobp.2020.07.1687, DOI 10.1016/J.IJROBP.2020.07.1687]
  • [10] Pseudoprogression and Immune-Related Response in Solid Tumors
    Chiou, Victoria L.
    Burotto, Mauricio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) : 3541 - +